This provides a rationale for targeting lipid metabolic regulators such as SREBP1 and SCD1 in PI3K/AKT/mTOR‐mutant cancers, thereby overcoming intrinsic resistance to ferroptosis. The gene discussed is MTOR; the disease is cancer.